Psyence Group Inc. (PSYG.CN) Research

Psyence Group Inc. is a life sciences biotechnology company primarily engaged in the commercial cultivation and production of psilocybin mushrooms. This naturally sourced psilocybin is intended for therapeutic applications, addressing a broad spectrum of mental health conditions and other medical ailments. The company is actively formulating pharmaceutical-grade psilocybin treatments designed to mitigate psychological trauma and recognized disorders such as anxiety, depression, post-traumatic stress disorder (PTSD), and the emotional distress linked to grief and bereavement. Furthermore, Psyence Group develops, distributes, and sells over-the-counter functional mushroom nutraceuticals, entirely free of psilocybin, under its GOODMIND brand. Established in 2019, the company maintains its headquarters in Toronto, Canada.

Market snapshot

Symbol
PSYG.CN
Price
$0.12
Day change
+9.09%
Market cap
$1.9M
P/E ratio
-0.12x
52-week range
0.105-0.375
Sector
Healthcare
Industry
Drug Manufacturers - General

Peer companies

  • Copland Road Capital Corporation (CRCC.CN)
  • Universal Ibogaine Inc. (IBO.V)
  • Doseology Sciences Inc. (MOOD.CN)
  • Ovation Science Inc. (OVAT.CN)
  • Planet Based Foods Global Inc. (PBF.CN)
  • Premier Health of America Inc. (PHA.V)
  • Pharmadrug Inc. (PHRX.CN)
  • RAMM Pharma Corp. (RAMM.CN)

Open Psyence Group Inc. (PSYG.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.